BioInformant

Your Global Leader in Stem Cell Market Research

Home » Coronavirus (COVID-19)

FibroGenesis Reports COVID-19 Breakthrough Using Fibroblast Cell Therapy (Pre-Clinical Trial Phase)

By Leave a Comment

PneumoBlast™ Reduces Pathology and Lung Fluid Accumulation in Model of COVID-19

HOUSTON, May 21, 2020 — FibroGenesis announced significant efficacy of its PneumoBlast™ product in an animal model of lung inflammation which resembles COVID-19.  Mice immune systems were stimulated to enter hyper-activation mode, which causes symptoms similar to COVID-19.  Once COVID-19 simulation was achieved, administration of PneumoBlast™ resulted in significant reduction in lung fluid accumulation.  Additionally, reduction was observed from infiltration of inflammatory cells, as well as suppression of chemical mediators such as interleukin-6 (IL-6), which are associated with poor survival in COVID-19 patients. [Read more…]

Organicell Reports Positive Results from Compassionate Use of Organicell Flow in Severely Ill COVID-19 Patients

By Leave a Comment

Miami, FL (May 27, 2020) ­– Organicell Regenerative Medicine, Inc. (OTCBB:BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today a health update for two critically ill COVID-19 patients who were treated at Landmark Hospital in Athens, GA with the Company’s Organicell Flow product. These patients were treated under the two recently approved Emergency Compassionate Use Investigational New Drug applications (eINDs) by the U.S. Food and Drug Administration (FDA). [Read more…]

FDA Approves Two Emergency INDs to Administer Organicell Flow for COVID-19

By Leave a Comment

First Patients treated with Organicell Flow through “Emergency Single Patient Compassionate Use” designation

MIAMI, May 19, 2020 — Organicell Regenerative Medicine, Inc. (OTCBB:BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that on May 11, 2020, the U.S. Food and Drug Administration (FDA) authorized two Emergency Compassionate Use Investigational New Drug applications (eINDs), each for a single patient severely ill from COVID-19. These critical patients have received immediate administration of Organicell Flow. [Read more…]

Funding for COVID-19 Countermeasures: Diagnostics, Vaccines, Treatments

By Leave a Comment

COVID-19 is a global emergency of unprecedented scale. Affecting all 7.2 billion people worldwide, it is largest pandemic in modern history. Because it could take a year or two before vaccines get approved, manufactured at high volume, and distributed on a global scale, there’s a dire need for treatments to reduce the mortality rate of the coronavirus while we wait. To this end, agencies around the world have been rapidly announcing funding support for the development of diagnostics, vaccines and therapeutics against COVID-19. [Read more…]

BioInformant's World-Class Clients